cytokine mobilization
Cytokine mobilization has been widely used over a decade, most often to collect peripheral blood stem cells (PBSC) as a cellular product used for hematopoietic support during autologous stem cell transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In contrast, cytokine-stimulated bone marrow stem cell (BMSC) autografts are rarely used. 11, 12 We investigated the committed and primitive progenitor content of autologous BMSC and PBSC grafts from patients with malignant non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) in order to understand the effects of cytokine stimulation on the BM or PB progenitor content and their relation to post transplant hematologic recovery.
Patients and methods

Patient characteristics
As shown (Table 1) , all patients were recipients of autologous hematopoietic stem cell grafts at the University of Minnesota. All but three of the 63 patients were adults and approximately 85% had NHL, with the remaining 15% having HD. A total of 25 patients had unprimed, unstimulated collections: 15 BM harvest and 10 PBSC apheresis. In all, 38 had cytokine-stimulated collections: 20 with G-CSF and 18 with GM-CSF as described. 10, 11 Patients' age, gender and primary diagnosis were similar in the six cohorts, those receiving BMSC or PBSC, either control, G-CSF-or GM-CSF-stimulated grafts.
Graft collection and mobilization
BM aspiration harvests were performed under general anesthesia by small volume (5-10 cm 3 ) aspirates from bilateral iliac crest sites to a target collection of 1.5 l. PBSC were collected by continuous flow apheresis using the Baxter-Fenwall CS3000*Plus set up for stem cell collections with a small volume collection chamber. Unstimulated control PBSC were collected in four daily consecutive aphereses processing 10-12 l of blood per day. 10, 11 Cytokine mobilization prior to collection used either GM-CSF (250 mg/m 2 /day injected subcutaneously rounded to vial size; for example, 250 mg/day for patients o1.2 m 2 or 500 mg for patients over 1.2 m 2 ) or G-CSF (250 mg/m 2 /day rounded to vial size; 300 or 480 mg/day). Stimulated BM harvests were collected on day 6 after 5 days of cytokine. Stimulated PBSC were collected on days 6-9 of daily cytokine therapy. Cytokines used for mobilization were assigned in random fashion. Patients studied represented a subset of those participating in two trials comparing BMSC to PBSC as control unstimulated or cytokine-mobilized samples. 10, 11 Transplants were performed as previously reported following preconditioning with cyclophosphamide and total body irradiation (TBI) for patients with NHL or cyclophosphamide, carmustine and etoposide for HD or for NHL patients ineligible to receive TBI safely. 10, 11 All previously collected and cryopreserved grafts were infused on day 0 and post transplant all patients received daily G-CSF (5 mg/kg/day rounded to vial size) until neutrophil recovery 42.5 Â 10 9 /l for 2 consecutive days. All treatment protocols were reviewed and approved by the University of Minnesota Institutional Review Board and all subjects exercised written informed consent prior to treatment.
In vitro progenitor culture
Aliquots of BM harvests or PBSC apheresis collections were cryopreserved in 10% human serum and 10% DMSO using controlled rate-freezing techniques and stored in the liquid phase of liquid nitrogen. The transplants were performed in separate cohorts under different treatment protocols. 10, 11 All cryopreserved samples were thawed and plated in one series of culture studies using consistent techniques. Aliquots were thawed, washed in sterile media and resuspended in Iscove's modified Dulbecco's medium (IMDM). Committed progenitors (CFU-GM) were cultured in methylcellulose containing IMDM supplemented with 30% fetal calf serum with erythropoietin (EPO, 3 IU/ ml) and 10% supernatant of bladder carcinoma cell line, 5637. After 14 days culture at 371C in humidified 5% CO 2 , myeloid colonies (CFU-GM) were counted using an inverted microscope and calculated in relation to the plated cellular inoculum. 13 More primitive progenitors, long-term culture-initiating cells (LTC-IC), were determined by plating thawed washed mononuclear cells on irradiated allogeneic BM stroma in IMDM supplemented with 12.5% fetal calf serum, 12.5% horse serum, 2 mmol/l glutamine, 100 U/ml penicillin, 100 U/ml streptomycin and 10 À6 mol/l hydrocortisone. After 5 weeks, all media were removed and overlaid with methylcellulose containing media supplemented with EPO and 5637 supernatant. After 14 additional days of culture, the presence of secondary CFU-GM was scored. 13 The progenitor frequency within the BM or PBSC grafts allowed calculation of the graft progenitor content in relation to the nucleated cell dose infused/kg recipient weight. CD34 determinations on the graft aliquots were not routinely performed and not available for analysis.
Statistical analysis
Clinical data were collected and monitored by the University of Minnesota Bone Marrow Transplant Database and Biostatistical Support Facility that contains prospectively collected data on all individuals transplanted at our center. Comparative analysis of progenitor content in grafts from different patient cohorts was performed using the general Wilcoxon's test to compare CFU-GM/kg and LTC-IC/kg between groups. For comparisons involving the four collections of PBSC, the mean yield of each patient's PBSC collection was multiplied by four. The ratio of patient group medians was used to estimate the fold increase in progenitors over the nonmobilized control groups. Confidence intervals of 95% were then generated around this statistic using bootstrap samples.
Hematopoietic engraftment was defined as the first of three serial post transplant measures of an absolute neutrophil count (ANC) 45 Â 10 8 /l, an untransfused platelet count 420 Â 10 9 /l and an untransfused hemoglobin 48.0 gm/dl. Correlation analysis of engraftment end points and the progenitor dose infused was performed using Spearman's rank-correlation coefficients. Patients who died before day þ 42 (n ¼ 2) without stable engraftment were excluded when calculating correlation estimates. Survivors beyond day þ 21 with failure of recovery in 1 or more lineages (n ¼ 3) were included in calculations and were assigned the highest rank of time to engraftment. Given that there were numerous comparisons of progenitor content and multilineage recovery, as a correction for BM cohort refers to patients transplanted using BM stem cells collected by aspiration harvest either without cytokine stimulation (control) or following 5 days of cytokine therapy using either G-CSF or GM-CSF. PBSC refers to patients receiving apheresis-collected blood progenitors collected over 4 days either immobilized or following cytokine stimulation (collection days 6-9).
Progenitor content of autologous grafts multiple testing, a P-value o0.01 was used to indicate statistical significance for these clinical correlations. Threshold doses were sought to determine the lowest dose at which the majority of subjects reached hematopoietic recovery at standard times.
Results
Cytokine mobilization of primitive and committed hematopoietic progenitors
Mobilized grafts compared to controls. The progenitor content within the BM and PBSC grafts is shown in Table 2 . Cytokine-mobilized BM collections using either G-CSF or GM-CSF contained significantly (11-29-fold) more primitive progenitors (LTC-IC/kg) than resting BM harvests (Table 2b , P ¼ 0.05). Somewhat greater LTC-IC content of G-CSF-stimulated BM was apparent compared to GM-CSF-stimulated BM (P ¼ 0.07). Analysis of the committed progenitor content of BM grafts showed that G-CSF, but not GM-CSF pretreatment, led to significant, 2.5-fold augmentation of the committed progenitor content (CFU-GM/kg) over control, unstimulated BM grafts. Cytokine stimulation augmented the progenitor content of the PBSC grafts to a lesser extent than that observed in BM. PB grafts mobilized with G-CSF contained 3.6-fold more CFU-GM/kg and 2.6-fold more LTC-IC/kg compared to unstimulated PBSC. In contrast, GM-CSFmobilized PBSC contained only 0.9-fold CFU-GM/kg and 1.2-fold more LTC-IC/kg than control PB grafts.
G-CSF stimulated the CFU-GM content of both BM and PBSC grafts to a similar extent. As shown in Table 2 , G-CSF-stimulated BM contained a median 2.5-fold increased content of CFU-GM over control BM, while G-CSF-stimulated PB had a 3.6-fold increase over control PBSC. However, G-CSF led to a 28.7-fold median increase in BM LTC-IC/kg, although only a small and nonsignificant increment in PBSC LTC-IC. In contrast, GM-CSF significantly enhanced the LTC-IC content (11.5-fold) over control BM, but did not increase the CFU-GM content of BM (1.1-fold).
PBSC grafts compared to BM. PBSC grafts contained a mean of 1.87-fold more nucleated cells/graft compared to BMSC. As shown in Table 2a , unstimulated PBSC grafts contained 12.8-fold more LTC-IC/kg than control BM grafts, while those primed with G-CSF and GM-CSF contained only 1.17-and 1.35-fold more LTC-IC/kg than BM grafts, respectively. The committed progenitor contents of PBSC and BMSC grafts were similar. PBSC contained 1.06-, 1.51-and 0.85-fold more CFU-GM/kg than BM grafts in control, G-CSF and GM-CSF primed grafts, respectively.
Hematologic recovery using cytokine-mobilized grafts
In serial patient cohorts, autotransplantation was performed using control grafts and using grafts collected after cytokine priming of BM and PB using either G-CSF or GM-CSF. Transplantation was followed by neutrophil engraftment (ANC 45 Â 10 8 /l) at a median of 13-16 days in the cytokine-mobilized cohorts compared to a median of 22 days in those receiving unmobilized BM or PB grafts (Table 3) . Later, more variable recovery of platelet and RBC production was observed. As shown, GM-CSF stimulation prior to BM harvests led to platelet and RBC engraftment at a median of 18 and 14 days, respectively, compared to a median of 25 and 20 days in the unstimulated BM controls. G-CSF stimulation of BM grafts yielded platelet and RBC recovery at a median of 27 days.
Transplantation using PBSC led to faster hematologic recovery. Grafts with G-CSF-mobilized PBSC were followed by engraftment for platelets and RBC at a median of 13 and 14 days, respectively. GM-CSF-mobilized PBSC did Table 2 Progenitor content (CFU-GM and LTC-IC) in control and cytokine-mobilized autologous grafts not lead to accelerated hematopoiesis with time to platelet recovery at median day 42 and RBC day 38, similar to control PBSC transplant platelet and RBC recovery at 38 and 27 days, respectively. Thus, G-CSF or GM-CSF mobilization of either BM or PB was associated with rapid neutrophil recovery. In contrast, GM-CSF, but not G-CSF stimulation of BM grafts led to somewhat more rapid platelet and RBC recovery. G-CSF, but not GM-CSF, mobilization of PB grafts accelerated both platelet and RBC recovery.
Graft progenitor content in relation to multilineage engraftment
We analyzed the infused dose of primitive and committed progenitors as potential predictors of the speed of post transplant engraftment. As shown in Table 4 , we observed no direct correlation between the infused progenitor dose (CFU/kg) and the speed of hematopoietic reconstitution of neutrophils, RBCs or platelets. No such correlation was observed in either G-CSF-or GM-CSF-stimulated BM or PBSC. Similarly, the infused dose of LTC-IC/kg did not correlate with the speed of trilineage engraftment following either GM-CSF-or G-CSF-stimulated BM or PBSC transplantation.
We also sought evidence for a threshold progenitor dose, above which prompt myeloid engraftment was assured. Disappointingly, we found no such threshold (data not shown). We also investigated a possible relationship between a minimum infused progenitor dose and subsequent delayed platelet or RBC recovery, but again found no such correlation.
Discussion
G-CSF and GM-CSF have a distinct functional impact on both the proliferation and translocation of primitive and committed progenitors into the blood and marrow.
2-5,12,14,15 While either cytokine may accelerate hematologic recovery after myelosuppressive therapy or stem cell transplantation, their comparative effect on the progenitor content of the autologous hematopoietic grafts is less certain. In this study, we compared both cytokinestimulated and control grafts collected from BM and PB. We observed that cytokine stimulation using either G-CSF or GM-CSF was more successful at mobilizing or expanding the number of more primitive stem cells (LTC-IC) in BM, but not in PB. Whereas G-CSF and GM-CSF have been shown to enhance the cell cycling fraction of CFU-GM in BM, 16 there has been only limited study of cytokine mobilization techniques on LTC-IC expansion in BMderived LTC-IC compared to those found in cytokinestimulated PB. 17 Our observation that cytokine stimulation produced more LTC-IC in BM compared to PB may suggest an intrinsic difference in LTC-IC subsets and their response to cytokines depending on location. 13 In BM progenitors, expansion without translocation is necessary, while in PB, expansion must be accompanied by translocation through altered adhesive interaction with BM stroma. In BM, G-CSF pretreatment was more effective than GM-CSF in augmenting the final BM graft content of LTC-IC. G-CSF was more effective than GM-CSF in mobilization of progenitors into PBSC, but for this compartment, CFU-GM were most effectively mobilized. Previous study by Ho (11) 16 (12-52) 42 38 (4-170) PBSC: control (10) 22 38 (14-93) 27 Median days (range) to recovery for neutrophil, platelet and RBC recovery after autologous stem cell transplantation are shown. Patients dying prior to day +21 (without recovery) were excluded, but later deaths without single lineage (n ¼ 2) or multilineage recovery (n ¼ 1) were analyzed as graft failure (total n ¼ 3). The Spearman rank-correlation coefficients (P-value) between progenitor dose infused/kg (CFU-GM and LTC-IC) and lineage-specific hematologic recovery following autotransplantation are shown. NE ¼ not evaluable (no5).
Progenitor content of autologous grafts et al, 14 showed G-CSF stimulation to be more effective than GM-CSF at mobilizing CFU-GM into PB. It is interesting that G-CSF increases the mobilization of more primitive progenitors into BM, but yields more committed progenitors in PB.
More rapid recovery of hematopoiesis can reduce mortality as well as the morbidity and cost of autologous transplantation.
2,3-5, 6, 15, [18] [19] [20] Current practice in graft evaluation to predict post transplant hematopoietic recovery is contingent on a sufficient CD34 þ transplant dose, where a dose of X5 Â 10 6 CD34 þ cells/kg delivers consistently rapid hematopoietic recovery. 21 Previous studies have shown that using PB autografts containing X5 Â 10 6 CD34 þ cells, neutrophil and platelet recovery within 9-12 days can be expected. 7, 8, 22 We observed modest differences in time to engraftment when comparing grafts mobilized with either G-CSF or GM-CSF. Transplants using GM-CSF-stimulated BM and G-CSF-stimulated PB showing earlier engraftment are compatible with the hypothesis, suggesting enrichment of marrow progenitors by GM-CSF and increased translocation of progenitors by G-CSF. 11, 22, 23 Combination studies of cytokines along with inhibitors of progenitor adhesion could enhance this enrichment even further, although most such investigations have focused on preclinical models. 24, 25 We investigated a relationship between either CFU-GM or LTC-IC dose as more accurate predictors of the time to engraftment. Although we observed that G-CSF and GM-CSF have differing capacity for LTC-IC and CFU-GM enhancement in BM or PB, the progenitor dose infused did not correlate with time to hematopoietic reconstitution. In fact, correlation coefficients across all groups did not suggest any trend supporting a biologic association with the engraftment end points. It is acknowledged that limited sample size and possible heterogeneity in prior chemotherapy and other clinical factors may limit the power of our analysis.
Sutherland et al 23 also found no correlation between the number of LTC-IC in PB with hematopoietic reconstitution. Previous studies have suggested a strong correlation between CFU-GM dose and hematopoietic reconstitution, 22, 23 although we observed neither a direct correlation nor a threshold dose of LTC-IC or CFU-GM predictive of hematopoietic reconstitution. 22, 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] Unavailability of CD34 graft content also compromised our study. Recently, Hogge et al reported that 90% of patients became platelet transfusion independent by 28 days post transplant if their grafts contained either 42 Â 10 6 CD34 þ cells/kg, 45 Â 10 5 total colony-forming cells (CFCs)/kg, or 41000 CFC in 5-week LTC-IC/kg. 35 Quantitation of phenotypic (CD34 þ , CD34 þ 38 À ) or clonogenic (cobblestone area-forming cells) progenitors can possibly define an inadequate graft, especially after intensive prior alkylatorbased chemotherapy. 36 Further study will be required for more reliable assessments of the quality of hematopoietic cells within a cryopreserved autograft. Recent interest in cytokine-stimulated BM allografts 37 as well as widespread application of G-CSF-mobilized PB allografts [38] [39] [40] further suggests the need for careful quantitative, as well as qualitative characterization of graft content.
